+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Respiratory Syncytial Virus Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025

  • ID: 4851983
  • Report
  • April 2018
  • Region: Global
  • 176 pages
  • Transparency Market Research
1 of 2

Global Respiratory Syncytial Virus (RSV) Therapeutics Market: Overview

Respiratory syncytial virus infection is highly contagious. It is reported to be the most common cause of pneumonia and bronchiolitis in children as well as adults. According to the Center for Disease and Prevention, around 25-40 of every 100 children exposed to RSV infection for the first time develop signs of bronchiolitis or pneumonia. No approved drugs have been available in the market to treat RSV infection till date, and only prophylaxis drugs have been used. Therefore, several biopharmaceutical companies are investing in research and development in order to develop new drugs and vaccine to treat or prevent the RSV infection.

The global respiratory syncytial virus (RSV) therapeutics market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drugs type, dosage form, distribution channel, and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. Additionally, the section comprises competitive matrix and company profiles with business overview in order to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global respiratory syncytial virus (RSV) therapeutics market.

Global Respiratory Syncytial Virus (RSV) Therapeutics Market: Key Segments

Based on drugs type, the global respiratory syncytial virus (RSV) therapeutics market can be segmented into palivizumab, ribavirin, and others. The drug type segments have been analyzed based on type of drug uses to treat RSV infection in the different region. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. According to dosage form, the global respiratory syncytial virus (RSV) therapeutics market can be classified into oral, injectable, and others. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

Global Respiratory Syncytial Virus (RSV) Therapeutics Market: Regional Outlook

In terms of geography, the global respiratory syncytial virus (RSV) therapeutics market has been categorized into five major regions and the key countries in the respective region: North America (the U.S., Canada), Europe (the U.K., Germany, France, Italy, Spain and Rest of Europe), Asia Pacific (China, Japan, India, Australia & New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico and Rest of Latin America) and Middle East and Africa (GCC Countries, South Africa, Israel, and Rest of MEA). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the respiratory syncytial virus (RSV) therapeutics market are include F. Hoffmann-La Roche Ltd., AstraZeneca plc, Merck & Co., Inc., AbbVie, Inc., Valeant Pharmaceuticals International, Inc, GlaxoSmithKline plc., ReViral Ltd., Gilead Sciences, Inc., and Teva Pharmaceutical Industries Ltd.

Note: Product cover images may vary from those shown
2 of 2
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary : Global Respiratory Syncytial Virus (RSV) Therapeutics Market

Chapter 4. Market Overview
4.1. Introduction
4.1.1. Product Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Pipeline Analysis - Respiratory Syncytial Virus (RSV) Therapeutics Market
4.4. Epidemiology Assessment - Respiratory Syncytial Virus (RSV) Therapeutics Market
4.5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, 2015-2025
4.5.1. Market Revenue Projection (US$ Mn)
4.5.2. Market Outlook
4.6. Key Trends

Chapter 5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Drugs Type
5.1. Key Findings/Developments
5.2. Introduction & Definition
5.3. Market Value Forecast, by Drugs Type, 2016-2025
5.3.1. Palivizumab
5.3.2. Ribavirin
5.3.3. Others
5.4. Market Attractiveness, by Drugs Type

Chapter 6. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Selection Technique
6.1. Key Findings/Developments
6.2. Introduction & Definition
6.3. Market Value and Volume Forecast, by Dosage Form, 2016-2025
6.3.1. Oral
6.3.2. Injectable
6.3.3. Others
6.4. Market Attractiveness, by Dosage Form

Chapter 7. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Distribution Channel
7.1. Key Findings/Developments
7.2. Introduction & Definition
7.3. Market Value and Volume Forecast, by Distribution Channel, 2017-2025
7.3.1. Drug Stores & Retail Pharmacies
7.3.2. Hospital Pharmacies
7.3.3. Others
7.4. Market Attractiveness, by Distribution Channel

Chapter 8. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Geography/Region
8.1. Geographical Representation
8.2. Market Value and Volume Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region

Chapter 9. North America Respiratory Syncytial Virus (RSV) Therapeutics Analysis and Forecast
9.1. Market Value Forecast, by Country , 2016-2025
9.1.1. U.S.
9.1.2. Canada
9.2. Market Value Forecast, by Drugs Type, 2016-2025
9.3. Market Value Forecast, by Dosage Form, 2016-2025
9.4. Market Value Forecast, by Distribution Channel, 2016-2025
9.5. Market Attractiveness Analysis
9.5.1. By Country
9.5.2. By Drugs Type
9.5.3. By Dosage Form
9.5.4. By Distribution Channel
9.6. Key Trends

Chapter 10. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
10.1. Market Value Forecast, by Country , 2017-2025
10.1.1. Germany
10.1.2. France
10.1.3. U.K.
10.1.4. Spain
10.1.5. Italy
10.1.6. Rest of Europe
10.2. Market Value Forecast, by Drugs Type, 2016-2025
10.3. Market Value Forecast, by Dosage Form, 2016-2025
10.4. Market Value Forecast, by Distribution Channel, 2016-2025
10.5. Market Attractiveness Analysis
10.5.1. By Country
10.5.2. By Drugs Type
10.5.3. By Dosage Form
10.5.4. By Distribution Channel
10.6. Key Trends

Chapter 11. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
11.1. Market Value Forecast, by Country , 2017-2025
11.1.1. China
11.1.2. Japan
11.1.3. India
11.1.4. Australia & New Zealand
11.1.5. Rest of APAC
11.2. Market Value Forecast, by Drugs Type, 2016-2025
11.3. Market Value Forecast, by Dosage Form, 2016-2025
11.4. Market Value Forecast, by Distribution Channel, 2016-2025
11.5. Market Attractiveness Analysis
11.5.1. By Country
11.5.2. By Drugs Type
11.5.3. By Dosage Form
11.5.4. By Distribution Channel
11.6. Key Trends

Chapter 12. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
12.1. Market Value Forecast, by Country, 2017-2025
12.1.1. Brazil
12.1.2. Mexico
12.1.3. Rest of LATAM
12.2. Market Value Forecast, by Drugs Type, 2016-2025
12.3. Market Value Forecast, by Dosage Form, 2016-2025
12.4. Market Value Forecast, by Distribution Channel, 2016-2025
12.5. Market Attractiveness Analysis
12.5.1. By Country
12.5.2. By Drugs Type
12.5.3. By Dosage Form
12.5.4. By Distribution Channel
12.6. Key Trends

Chapter 13. Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
13.1. Market Value Forecast, by Country, 2017-2025
13.1.1. GCC Countries
13.1.2. South Africa
13.1.3. Israel
13.1.4. Rest of Middle East & Africa
13.2. Market Value Forecast, by Drugs Type, 2016-2025
13.3. Market Value Forecast, by Dosage Form, 2016-2025
13.4. Market Value Forecast, by Distribution Channel, 2016-2025
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Drugs Type
13.5.3. By Dosage Form
13.5.4. By Distribution Channel
13.6. Key Trends

Chapter 14. Competition Landscape
14.1. Competition Matrix
14.1.1. Merck & Co., Inc.
14.1.2. F. Hoffmann-La Roche Ltd.
14.2. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
14.2.1. F. Hoffmann-La Roche Ltd. (HQ, Business Segments, Employee Strength)
14.2.1.1. Company Details
14.2.1.2. Company Description
14.2.1.3. Business Overview
14.2.1.4. SWOT Analysis
14.2.1.5. Financial Analysis
14.2.1.6. Strategic Overview
14.2.2. AstraZeneca plc. (HQ, Business Segments, Employee Strength)
14.2.2.1. Company Details
14.2.2.2. Company Description
14.2.2.3. Business Overview
14.2.2.4. SWOT Analysis
14.2.2.5. Strategic Overview
14.2.3. Merck 7 Co., Inc. (HQ, Business Segments, Employee Strength)
14.2.3.1. Company Details
14.2.3.2. Company Description
14.2.3.3. Business Overview
14.2.3.4. SWOT Analysis
14.2.3.5. Strategic Overview
14.2.4. AbbVie, Inc. (HQ, Business Segments, Employee Strength)
14.2.4.1. Company Details
14.2.4.2. Company Description
14.2.4.3. Business Overview
14.2.4.4. SWOT Analysis
14.2.4.5. Strategic Overview
14.2.5. Valeant Pharmaceuticals International, Inc. (HQ, Business Segments, Employee Strength)
14.2.5.1. Company Details
14.2.5.2. Company Description
14.2.5.3. Business Overview
14.2.5.4. SWOT Analysis
14.2.5.5. Financial Analysis
14.2.5.6. Strategic Overview
14.2.6. GlaxoSmithKline plc. (HQ, Business Segments, Employee Strength)
14.2.6.1. Company Details
14.2.6.2. Company Description
14.2.6.3. Business Overview
14.2.6.4. SWOT Analysis
14.2.6.5. Financial Analysis
14.2.6.6. Strategic Overview
14.2.7. ReViral Ltd. (HQ, Business Segments, Employee Strength)
14.2.7.1. Company Details
14.2.7.2. Company Description
14.2.7.3. Business Overview
14.2.7.4. SWOT Analysis
14.2.7.5. Financial Analysis
14.2.7.6. Strategic Overview
14.2.8. Gilead Sciences, Inc. (HQ, Business Segments, Employee Strength)
14.2.8.1. Company Details
14.2.8.2. Company Description
14.2.8.3. Business Overview
14.2.8.4. SWOT Analysis
14.2.8.5. Financial Analysis
14.2.8.6. Strategic Overview
14.2.9. MEDIVIR AB (HQ, Business Segments, Employee Strength)
14.2.9.1. Company Details
14.2.9.2. Company Description
14.2.9.3. Business Overview
14.2.9.4. SWOT Analysis
14.2.9.5. Strategic Overview
14.2.10. Teva Pharmaceuticals Industries Ltd. (HQ, Business Segments, Employee Strength)
14.2.10.1. Company Details
14.2.10.2. Company Description
14.2.10.3. Business Overview
14.2.10.4. SWOT Analysis
14.2.10.5. Strategic Overview
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll